Impact of Opioid Use in Hematological Malignancies: Clinical, Immunological and Concomitant Aspects.

Polina Tregubenko, Valeriy Zvonarev
Author Information
  1. Polina Tregubenko: Internal Medicine Residency Program, Albert Einstein College of Medicine, Jacobi Medical Center, Bronx, NY, USA.
  2. Valeriy Zvonarev: School of Behavioral Sciences, California Southern University, Costa Mesa, CA, USA.

Abstract

Opioid agents play a unique role in pain and symptom management for cancer patients. Research shows that opiate use, especially when associated with underlying cancer, has significant effects on hematological parameters. These changes may lead to greater risk for immunosuppression, tumor growth and progression of metastatic processes. The aim of this review is to explore the effects of opiates on various metabolic and biological processes, as well as the hematopoietic system, especially in cancer patients. Our findings demonstrate that the tumor-promoting effects of opiates remain contradictory, as both growth-promoting and anti-tumor effects have been observed. However, available data suggest that opiates can facilitate the proliferation and migration of tumor cells, and understanding of this process on cancer treatment is tremendously important.

Keywords

References

  1. Integr Cancer Ther. 2007 Sep;6(3):293-6 [PMID: 17761642]
  2. J Clin Anesth. 2005 Dec;17(8):575-80 [PMID: 16427525]
  3. Front Microbiol. 2015 Nov 04;6:1230 [PMID: 26583016]
  4. Nature. 1990 Sep 27;347(6291):394-6 [PMID: 1699130]
  5. Aust N Z J Public Health. 2011 Jun;35(3):220-5 [PMID: 21627721]
  6. Leuk Res. 2011 Dec;35(12):1649-57 [PMID: 21798596]
  7. Arch Intern Med. 1974 Dec;134(6):1001-6 [PMID: 4433182]
  8. J Exp Clin Cancer Res. 2005 Jun;24(2):255-63 [PMID: 16110759]
  9. Addict Health. 2016 Fall;8(4):252-260 [PMID: 28819556]
  10. Biochem Biophys Res Commun. 1998 Apr 17;245(2):392-6 [PMID: 9571161]
  11. Int J Oncol. 2016 Aug;49(2):793-802 [PMID: 27279602]
  12. J Biol Chem. 2003 Dec 5;278(49):49254-60 [PMID: 14504289]
  13. Cureus. 2018 Jul 5;10(7):e2924 [PMID: 30197847]
  14. Ann Med Surg (Lond). 2018 Nov 22;37:38-41 [PMID: 30581568]
  15. Addict Health. 2010 Winter-Spring;2(1-2):9-16 [PMID: 24494095]
  16. Oral Health Dent Manag. 2014 Sep;13(3):721-4 [PMID: 25284545]
  17. Anticancer Res. 2011 Dec;31(12):4561-8 [PMID: 22199331]
  18. J Neuroimmunol. 1998 Mar 15;83(1-2):63-9 [PMID: 9610674]
  19. Biochim Biophys Acta. 2010 Nov;1802(11):1036-47 [PMID: 20691259]
  20. FEBS Lett. 1996 Apr 1;383(3):230-2 [PMID: 8925902]
  21. J Natl Cancer Inst. 1987 Nov;79(5):1059-65 [PMID: 2824913]
  22. Cochrane Database Syst Rev. 2017 Jul 06;7:CD012592 [PMID: 28683172]
  23. Int Immunopharmacol. 2006 Aug;6(8):1331-40 [PMID: 16782547]
  24. Int J Immunopharmacol. 1985;7(6):865-74 [PMID: 3000961]
  25. Int J Neurosci. 1991 Jul;59(1-3):127-33 [PMID: 1774133]
  26. J Neuroimmunol. 1996 Jan;64(1):29-36 [PMID: 8598387]
  27. Anesthesiology. 2011 Dec;115(6):1363-81 [PMID: 22020140]
  28. Int J Immunopharmacol. 1996 Oct;18(10):577-86 [PMID: 9080251]
  29. Ann Intern Med. 1978 Jun;88(6):793-5 [PMID: 78676]
  30. Br J Pharmacol. 1997 Jun;121(4):834-40 [PMID: 9208156]
  31. J BUON. 2017 Jan-Feb;22(1):112-118 [PMID: 28365943]
  32. J Opioid Manag. 2011 Sep-Oct;7(5):353-61 [PMID: 22165034]
  33. J Investig Med. 2002 Nov;50(6):435-42 [PMID: 12425430]
  34. Immunopharmacology. 1992 Jan-Feb;23(1):57-61 [PMID: 1314788]
  35. Immunopharmacology. 2000 Apr;47(1):53-62 [PMID: 10708810]
  36. Br J Cancer. 2014 Aug 26;111(5):866-73 [PMID: 25025960]
  37. Immunol Lett. 1993 May;36(2):215-8 [PMID: 8394283]
  38. Transl Psychiatry. 2016 Mar 15;6:e757 [PMID: 26978739]
  39. Biomed Pharmacother. 2002 Nov;56(9):458-62 [PMID: 12481982]
  40. PLoS One. 2016 Jul 05;11(7):e0158641 [PMID: 27379802]
  41. Exp Biol Med (Maywood). 2011 Jul;236(7):883-95 [PMID: 21685240]
  42. Anesthesiology. 2016 Jan;124(1):69-79 [PMID: 26556730]
  43. PLoS One. 2010 Feb 19;5(2):e9205 [PMID: 20174568]
  44. Int J Oncol. 2005 Nov;27(5):1329-39 [PMID: 16211229]
  45. Virology. 2003 Apr 25;309(1):99-107 [PMID: 12726730]
  46. J Leukoc Biol. 2000 Nov;68(5):723-8 [PMID: 11073113]
  47. PLoS One. 2019 May 17;14(5):e0216358 [PMID: 31100066]
  48. J Leukoc Biol. 1991 Oct;50(4):349-55 [PMID: 1717622]
  49. J Pharmacol Exp Ther. 1988 Jun;245(3):913-20 [PMID: 3385646]
  50. Am J Med. 1973 Mar;54(3):320-6 [PMID: 4631942]
  51. Oncotarget. 2013 May;4(5):677-90 [PMID: 23633472]
  52. Front Immunol. 2019 Dec 20;10:2904 [PMID: 31921165]
  53. Ann N Y Acad Sci. 1987;496:115-25 [PMID: 3300468]
  54. Ann N Y Acad Sci. 1988;521:123-8 [PMID: 3288038]
  55. Drug Alcohol Depend. 2001 Apr 1;62(2):111-23 [PMID: 11245967]
  56. Int J Clin Exp Pathol. 2014 Oct 15;7(11):7708-16 [PMID: 25550807]
  57. Acta Med Croatica. 2000;54(3):99-105 [PMID: 11268793]
  58. Toxicology. 2009 Feb 4;256(1-2):83-91 [PMID: 19070643]
  59. Biochem Biophys Res Commun. 2019 Dec 10;520(3):560-565 [PMID: 31615652]
  60. Exp Cell Res. 2009 Jul 15;315(12):2115-25 [PMID: 19362548]
  61. Am J Hematol. 1999 Mar;60(3):229-30 [PMID: 10072116]
  62. Daru. 2015 Feb 20;23:16 [PMID: 25890335]
  63. Carcinogenesis. 1996 Nov;17(11):2337-41 [PMID: 8968046]
  64. Naunyn Schmiedebergs Arch Pharmacol. 1989 Jul;340(1):101-6 [PMID: 2552328]
  65. Psychoneuroendocrinology. 1993;18(2):141-8 [PMID: 8388112]
  66. Toxicol Mech Methods. 2015;25(5):388-95 [PMID: 25980655]
  67. J Neuroimmune Pharmacol. 2006 Mar;1(1):77-89 [PMID: 18040793]
  68. Oncogene. 2017 Oct 19;36(42):5910-5913 [PMID: 28650467]
  69. Anticancer Res. 2015 Mar;35(3):1311-9 [PMID: 25750280]
  70. Blood. 2013 Nov 14;122(20):3403 [PMID: 24369032]
  71. Am J Ther. 2004 Sep-Oct;11(5):354-65 [PMID: 15356431]
  72. BMJ Case Rep. 2014 Mar 03;2014: [PMID: 24591390]
  73. J Neuroimmunol. 1994 May;51(2):169-76 [PMID: 7514185]
  74. J Allergy Clin Immunol. 1973 Mar;51(3):152-60 [PMID: 4631663]
  75. Int J Clin Pharmacol Ther. 2014 Aug;52(8):669-75 [PMID: 24755130]
  76. Otolaryngol Pol. 1989;43(1):12-8 [PMID: 2554241]
  77. Ann N Y Acad Sci. 2002 Jun;965:497-514 [PMID: 12105125]
  78. J Opioid Manag. 2011 Mar-Apr;7(2):93-6 [PMID: 21561032]
  79. Addict Biol. 2002 Apr;7(2):207-17 [PMID: 12006216]
  80. Cell Immunol. 1999 Jan 10;191(1):34-48 [PMID: 9918685]
  81. BMJ Case Rep. 2018 Aug 27;2018: [PMID: 30150344]
  82. FEBS Lett. 2002 May 22;519(1-3):173-7 [PMID: 12023039]
  83. Am J Kidney Dis. 2014 Jun;63(6):1022-6 [PMID: 24529995]
  84. Mol Immunol. 2010 Nov-Dec;48(1-3):257-63 [PMID: 20828825]
  85. Surgery. 2001 Aug;130(2):304-9 [PMID: 11490364]
  86. Int Immunopharmacol. 2010 Sep;10(9):1149-52 [PMID: 20609402]
  87. Brain Behav Immun. 2007 Aug;21(6):767-74 [PMID: 17291715]
  88. Br J Pharmacol. 2018 Jul;175(14):2726-2736 [PMID: 28593737]
  89. Life Sci. 1988;43(6):v-xi [PMID: 2841547]
  90. Br J Cancer. 2001 Mar 2;84(5):587-93 [PMID: 11237376]
  91. J Neuroimmunol. 2006 May;174(1-2):101-7 [PMID: 16529824]
  92. Neuroimmunomodulation. 2004;11(4):255-60 [PMID: 15249732]
  93. AJP Rep. 2016 Mar;6(1):e129-32 [PMID: 26989567]
  94. Exp Ther Med. 2016 Aug;12(2):559-566 [PMID: 27446244]
  95. JAMA. 1974 Nov 4;230(5):721 [PMID: 4606811]
  96. Can J Physiol Pharmacol. 2004 Nov;82(11):1018-25 [PMID: 15644942]
  97. Neurosci Lett. 2006 Jul 31;403(1-2):1-5 [PMID: 16687214]
  98. Curr Opin Support Palliat Care. 2014 Jun;8(2):91-101 [PMID: 24759319]
  99. J Immunol. 2002 Oct 1;169(7):3589-99 [PMID: 12244149]
  100. Anticancer Res. 2006 Sep-Oct;26(5A):3343-8 [PMID: 17094451]
  101. Life Sci. 1998;62(14):1251-9 [PMID: 9570340]
  102. Biol Pharm Bull. 1993 Aug;16(8):762-6 [PMID: 8220322]
  103. Cancer Res. 2010 Apr 15;70(8):3259-68 [PMID: 20354190]
  104. Leuk Lymphoma. 2015 Jun;56(6):1903-5 [PMID: 25363399]
  105. J Pain Symptom Manage. 2006 Dec;32(6):532-40 [PMID: 17157755]
  106. J Neuroimmunol. 2002 Aug;129(1-2):18-24 [PMID: 12161016]
  107. Int Immunopharmacol. 2003 May;3(5):707-11 [PMID: 12757739]
  108. Clin Immunol Immunopathol. 1986 Nov;41(2):247-53 [PMID: 3021364]
  109. Microbiol Mol Biol Rev. 2004 Jun;68(2):320-44 [PMID: 15187187]
  110. Int Immunopharmacol. 2018 Aug;61:178-184 [PMID: 29885638]
  111. J Pharmacol Exp Ther. 1993 Oct;267(1):9-15 [PMID: 7693915]
  112. Anesth Analg. 1998 Jan;86(1):166-72 [PMID: 9428873]
  113. Anesth Analg. 2000 Jun;90(6):1411-4 [PMID: 10825330]
  114. Biochem Biophys Res Commun. 1998 Nov 27;252(3):566-70 [PMID: 9837747]
  115. Molecules. 2014 Aug 08;19(8):11846-59 [PMID: 25111025]

Word Cloud

Created with Highcharts 10.0.0cancereffectsopiatesOpioidpatientsespeciallytumorprocessessystemagentsplayuniquerolepainsymptommanagementResearchshowsopiateuseassociatedunderlyingsignificanthematologicalparameterschangesmayleadgreaterriskimmunosuppressiongrowthprogressionmetastaticaimreviewexplorevariousmetabolicbiologicalwellhematopoieticfindingsdemonstratetumor-promotingremaincontradictorygrowth-promotinganti-tumorobservedHoweveravailabledatasuggestcanfacilitateproliferationmigrationcellsunderstandingprocesstreatmenttremendouslyimportantImpactUseHematologicalMalignancies:ClinicalImmunologicalConcomitantAspectsCancerImmuneLeukemiaLymphomaMetastasisMorphineOncologyOpioids

Similar Articles

Cited By